Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

Researchers at Uppsala University and KTH Royal Institute of Technology have developed a new form of precision medicine, an ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Phase 2 Long COVID Results Expected Soon Dogwood Therapeutics, Inc.

Autolus is confident in its supply chain after it was already been tested under “the most difficult circumstances” during its FELIX study over the peak of the COVID-19 pandemic. Currently, the product ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus.

(RTTNews) - Novavax, Inc. (NVAX) Monday said the Food and Drug Administration or FDA has removed the clinical hold on its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine ...

Novavax, Inc. , a global company advancing protein-based vaccines with its Matrix-Mtm adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on ...

Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable diseaseColon ...

Novavax (NVAX) shares surge 12% as FDA lifts clinical hold on COVID-19-Influenza Combination vaccine candidates.